Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies

Page 3 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.

• In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)RecruitingNCT04785989
• Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.RecruitingNCT04771572Phase 1
• A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04771507Phase 1/2
• Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04758975Phase 2
• CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic LeukemiaRecruitingNCT04704323Phase 1
• Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy AdherenceRecruitingNCT04663100Not applicable
• Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic LeukemiaRecruitingNCT04616274
• Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLRecruitingNCT04588922Phase 1/2
• ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLRecruitingNCT04578613Phase 3
• Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaRecruitingNCT04545762Phase 1
• Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT04494503Phase 1/2
• The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/2
• CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/2
• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingNCT04269902Phase 3
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
• CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell MalignanciesRecruitingNCT04186520Phase 1/2
• Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT04169737Phase 2
• Understanding Chronic Lymphocytic LeukemiaRecruitingNCT04028531
• Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)RecruitingNCT03986034Phase 2
• A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingNCT03980002Phase 2
• Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingNCT03852407Phase 2
• CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic MalignanciesRecruitingNCT03765177Phase 1/2
• Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CARRecruitingNCT03676504Phase 1/2
• Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT03666000Phase 1
• Gazyva Infusion Reaction InvestigationRecruitingNCT03529227
• Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT03516617Phase 2
• Evaluation of Human Immune Responses Vaccination in Patients With LymphomaRecruitingNCT03501576
• A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and LeukemiaRecruitingNCT03383952Phase 1
• Long-term Follow-up Study of Patients Receiving CAR-T CellsRecruitingNCT03375619
• Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingRecruitingNCT03342144
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
• Chronic Lymphoid Leukaemia Observatory in Finistere Area, FranceRecruitingNCT03294980
• Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National StudyRecruitingNCT03197259
• Expanded Access to VenetoclaxAvailableNCT03123029
• Institut Paoli Calmettes Chronic Lymphatic Leukemia DatabaseRecruitingNCT02869529
• Cancer Experience Registry (CER) for Cancer Patients and CaregiversRecruitingNCT02333604
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
• Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)RecruitingNCT01853631Phase 1
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer TreatmentRecruitingNCT01087333
• Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)RecruitingNCT00923507
• Family Study of Lymphoproliferative DisordersRecruitingNCT00626496
• Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruitingNCT00131014
• RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedNCT05405309Phase 1/2Results posted
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)CompletedNCT05105841Phase 2Results posted
• COVID-19 VAX Booster Dosing in Patients With Hematologic MalignanciesCompletedNCT05028374Phase 2Results posted
• A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT05023980Phase 3Results posted
• Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL PatientsCompletedNCT04981912Phase 1Results posted
• Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompletedNCT04930536Phase 4Results posted
• A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)CompletedNCT04849416Phase 2Results posted
• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)TerminatedNCT04809467Phase 1/2Results posted
• Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT04666038Phase 3Results posted
• Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04659044Phase 2Results posted
• Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT04657094Phase 2Results posted
• Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLActive, not recruitingNCT04624633Phase 2Results posted
• Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedNCT04599634Phase 1Results posted
• APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)TerminatedNCT04419389Phase 1/2Results posted
• First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin LymphomasTerminatedNCT04358458Phase 1/2Results posted
• Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 2Results posted
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 MutationCompletedNCT04285567Phase 3Results posted
• Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabCompletedNCT04282018Phase 1/2Results posted
• Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT StudyTerminatedNCT04230304Phase 2Results posted
• Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04209621Phase 2Results posted
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesCompletedNCT04205409Phase 2Results posted
• Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT04204057Phase 2Results posted
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
• Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminatedNCT04189952Phase 2Results posted
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT04163718Phase 2Results posted
• T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin LymphomaTerminatedNCT04160195Phase 1Results posted
• Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
• Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyTerminatedNCT04149821Phase 2Results posted
• Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT04075292Phase 3Results posted
• Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04060277Phase 2Results posted
• Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLCompletedNCT04030195Phase 1/2Results posted
• Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedNCT04016805Phase 2Results posted
• Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsCompletedNCT04008706Phase 3Results posted
• Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT03961672Phase 2Results posted
• Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesActive, not recruitingNCT03932331Phase 1/2Results posted
• Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedNCT03828448Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)TerminatedNCT03801525Phase 2/3Results posted
• Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaCompletedNCT03788291Phase 2Results posted
• An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedNCT03779113Phase 1Results posted
• Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK InhibitorsCompletedNCT03771157Early Phase 1Results posted
• Project to Improve Communication About Serious Illness - Pilot StudyCompletedNCT03746392Not applicableResults posted
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT03737981Phase 3Results posted
• Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
• A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaCompletedNCT03734016Phase 3Results posted
• Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)CompletedNCT03702231Phase 2Results posted
• HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)CompletedNCT03685708Phase 2Results posted
• Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaTerminatedNCT03624036Phase 1Results posted
• Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsTerminatedNCT03615105Phase 2Results posted
• Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaCompletedNCT03609593Phase 2Results posted
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive, not recruitingNCT03580928Phase 2Results posted
• Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLLTerminatedNCT03572634Phase 1/2Results posted
• CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic TransplantActive, not recruitingNCT03560752Phase 1Results posted
• Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSActive, not recruitingNCT03534323Phase 1/2Results posted
• Ibrutinib and PD-1 Blockade in High Risk Lymphocytic LeukemiaTerminatedNCT03514017Phase 2Results posted
• A Study Of The Selective PKC-β Inhibitor MS- 553TerminatedNCT03492125Phase 1/2Results posted

← Leukemia, Lymphocytic, Chronic, B-Cell overview